Lexology February 17, 2024
Hogan Lovells

The U.S. Food and Drug Administration (FDA) continues its efforts to include diverse participants in clinical research with a newly-published revision to its draft guidance document entitled, “Collection of Race and Ethnicity Data in Clinical Trials,” which provides recommendations on the standardized collection of race and ethnicity data. Although we continue to await FDA guidance on diversity action plans, this latest guidance suggests the agency is laying the groundwork for additional guidance promoting clinical trial diversity. FDA is seeking comments on the draft guidance through April 29, 2024.

FDA originally published final guidance on the collection of race and ethnicity data in clinical trials in 2016, in response to the Office of Management and Budget (OMB) Statistical Policy Directive 15,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Equity/SDOH, FDA, Govt Agencies, Healthcare System, Patient / Consumer
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article